These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 10559625)

  • 1. Management of symptomatic BPH in the US: who is treated and how?
    Bruskewitz R
    Eur Urol; 1999; 36 Suppl 3():7-13. PubMed ID: 10559625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of symptomatic BPH in the UK: who is treated and how?
    McNicholas TA
    Eur Urol; 1999; 36 Suppl 3():33-9. PubMed ID: 10559629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of symptomatic BPH in France: who is treated and how?
    Lukacs B
    Eur Urol; 1999; 36 Suppl 3():14-20. PubMed ID: 10559626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of symptomatic BPH in Italy: who is treated and how?
    Tubaro A; Montanari E
    Eur Urol; 1999; 36 Suppl 3():28-32. PubMed ID: 10559628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Terazosin. A pharmacoeconomic evaluation of its use in benign prostatic hyperplasia.
    Plosker GL; Goa KL
    Pharmacoeconomics; 1997 Feb; 11(2):184-97. PubMed ID: 10165827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia.
    Lowe FC; McDaniel RL; Chmiel JJ; Hillman AL
    Urology; 1995 Oct; 46(4):477-83. PubMed ID: 7571214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of the BPH syndrome in Germany: who is treated and how?
    Berges RR; Pientka L
    Eur Urol; 1999; 36 Suppl 3():21-7. PubMed ID: 10559627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The American Urological Association symptom score in the evaluation of men with lower urinary tract symptoms: at 2 years of followup, does it work?
    Kaplan SA; Olsson CA; Te AE
    J Urol; 1996 Jun; 155(6):1971-4. PubMed ID: 8618299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benign prostatic hyperplasia. Practical treatment guidelines.
    Tammela T
    Drugs Aging; 1997 May; 10(5):349-66. PubMed ID: 9143856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lower urinary tract symptoms/benign prostatic hyperplasia: maintaining symptom control and reducing complications.
    O'Leary MP
    Urology; 2003 Sep; 62(3 Suppl 1):15-23. PubMed ID: 12957196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The long-term cost effectiveness of treatments for benign prostatic hyperplasia.
    DiSantostefano RL; Biddle AK; Lavelle JP
    Pharmacoeconomics; 2006; 24(2):171-91. PubMed ID: 16460137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
    Lepor H; Williford WO; Barry MJ; Haakenson C; Jones K
    J Urol; 1998 Oct; 160(4):1358-67. PubMed ID: 9751354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
    Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Latest trends and recommendations on epidemiology, diagnosis, and treatment of benign prostatic hyperplasia (BPH)].
    Gabuev A; Oelke M
    Aktuelle Urol; 2011 May; 42(3):167-78. PubMed ID: 21604233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function.
    Li MK; Garcia L; Patron N; Moh LC; Sundram M; Leungwattanakij S; Pripatnanont C; Cheng C; Chi-Wai M; Loi-Cheong N
    BJU Int; 2008 Jan; 101(2):197-202. PubMed ID: 18005205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lower urinary tract symptoms suggestive of benign prostatic obstruction: what are the current practice patterns?
    McNicholas TA
    Eur Urol; 2001; 39 Suppl 3():26-30. PubMed ID: 11275739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benign prostatic hyperplasia: a review.
    Ramsey EW
    Can J Urol; 2000 Dec; 7(6):1135-43. PubMed ID: 11151094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted County, Minnesota: 1987 to 1997.
    Sarma AV; Jacobson DJ; McGree ME; Roberts RO; Lieber MM; Jacobsen SJ
    J Urol; 2005 Jun; 173(6):2048-53. PubMed ID: 15879823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Who should be treated and how? Evidence-based medicine in symptomatic BPH.
    Speakman MJ
    Eur Urol; 1999; 36 Suppl 3():40-51. PubMed ID: 10559630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function.
    Miner M; Rosenberg MT; Perelman MA
    Clin Ther; 2006 Jan; 28(1):13-25. PubMed ID: 16490576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.